Eris Lifesciences Share Price | Eris Lifesciences Stock Screener
ERIS
Pharmaceuticals
Share Price NSE
₹1350.80
▼
-10.60 (-0.78%)
Share Price BSE
₹1350.80
▼
-10.35 (-0.76%)
As of May 27, 2026, the Eris Lifesciences share price (NSE: ERIS) is ₹1,350.80 on NSE and ₹1,350.80 on BSE, down 0.78% from the previous close, with shares trading between ₹1,350.00 and ₹1,374.90, and a 52-week range of ₹1,271.00–₹1,847.70.
Check Eris Lifesciences 52-week for the annual price range and momentum.
Use the Eris Lifesciences stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Eris Lifesciences Market Cap
₹18,848.76 Cr.
ERIS P/E Ratio (TTM)
28.77
Eris Lifesciences P/B Ratio
4.80
EPS (TTM)
₹45.33
Dividend Yield
0.54%
Debt to Equity
0.97
ERIS 52 Week High
₹1847.70
Eris Lifesciences 52 Week Low
₹1271.00
Operating Margin
36.00%
Profit Margin
36.95%
ERIS Revenue (TTM)
₹755.00
EBITDA
₹270.00
Net Income
₹279.00
Total Assets
₹7,366.00
Total Equity
₹3,903.00
Eris Lifesciences Share Price Chart
Screen Eris Lifesciences share price with an interactive chart. Analyse ERIS price trends and volatility across different timeframes.
Eris Lifesciences Company Profile - Fundamental Screener
Screen Eris Lifesciences company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for ERIS shares.
Eris Lifesciences Limited is an Indian company that manufactures and markets pharmaceutical products. Founded in 2007, the company operates a manufacturing plant in Guwahati, Assam. Eris focuses on chronic, sub-chronic, and acute therapeutic areas, including cardiovascular, anti-diabetics, vitamins, gastroenterology, and anti-infective. The company has a portfolio of 112 Mother Brands...more
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
Amit Indubhushan Bakshi
ISIN
INE406M01024
Website
https://www.eris.co.in
Eris Lifesciences Balance Sheet Screener
Screen ERIS balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 7,366 | 7,033 | 7,041 | 3,667 | 2,272 | 1,835 | 1,552 | 1,554 | 1,460 | 727 |
| Current Assets | 1,540 | 1,223 | 2,302 | 765 | 627 | 467 | 480 | 582 | 299 | 216 |
| Fixed Assets | 4,447 | 5,307 | 4,319 | 2,568 | 918 | 854 | 875 | 761 | 771 | 232 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 1,393 | 2,380 | 1,286 | 1,003 | 164 | 91 | 91 | 79 | 349 | 60 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 3,903 | 3,272 | 3,222 | 2,221 | 1,908 | 1,576 | 1,296 | 1,169 | 886 | 591 |
| Share Capital | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
| Reserves & Surplus | 3,889 | 2,841 | 2,573 | 2,182 | 1,894 | 1,563 | 1,283 | 1,137 | 848 | 553 |
Eris Lifesciences Income Statement Screener - Profit & Revenue Analysis
Screen Eris Lifesciences income statement and profit fundamentals.
Analyze ERIS quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Eris Lifesciences share price evaluation.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 755 | 711 | 775 | 793 | 801 | 562 | 717 | 744 | 726 | 398 | 461 | 504 | 488 | 309 | 395 |
| Expenses | 484 | 453 | 496 | 504 | 543 | 403 | 470 | 477 | 477 | 284 | 297 | 324 | 311 | 209 | 269 |
| EBITDA | 270 | 258 | 279 | 289 | 258 | 160 | 248 | 267 | 249 | 114 | 164 | 180 | 177 | 100 | 125 |
| Operating Profit % | 36.00% | 36.00% | 36.00% | 36.00% | 32.00% | 26.00% | 34.00% | 35.00% | 34.00% | 28.00% | 35.00% | 35.00% | 36.00% | 31.00% | 31.00% |
| Depreciation | 70 | 77 | 71 | 69 | 70 | 54 | 76 | 81 | 81 | 35 | 41 | 42 | 46 | 18 | 23 |
| Interest | 46 | 54 | 49 | 50 | 49 | 33 | 60 | 60 | 57 | 9 | 17 | 16 | 18 | 1 | 7 |
| Profit Before Tax | 159 | 129 | 161 | 173 | 145 | 77 | 116 | 129 | 116 | 76 | 113 | 126 | 116 | 85 | 101 |
| Tax | -120 | 27 | 36 | 38 | 37 | -3 | 26 | 33 | 29 | 14 | 19 | 4 | 14 | 5 | 8 |
| Net Profit | 279 | 102 | 125 | 135 | 109 | 80 | 90 | 96 | 87 | 62 | 94 | 122 | 102 | 80 | 93 |
| EPS | 20.60 | 6.90 | 8.66 | 8.82 | 7.32 | 5.22 | 6.11 | 6.73 | 6.16 | 4.81 | 6.97 | 9.08 | 7.55 | 5.91 | 6.96 |
Eris Lifesciences Cash Flow Screener - Liquidity Fundamentals
Screen ERIS cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 1,065 | 486 | 292 | 378 | 375 | 271 | 223 | 235 | 200 | 132 |
| Investing Activities | -78 | -1,828 | -975 | -320 | -323 | 123 | -5 | -590 | -185 | -44 |
| Financing Activities | -881 | 1,380 | 688 | -45 | -82 | -335 | -221 | 363 | -24 | -84 |
| Net Cash Flow | 106 | 38 | 5 | 14 | -30 | 60 | -3 | 8 | -8 | 4 |
Eris Lifesciences Shareholding Pattern Screener
See Eris Lifesciences shareholding pattern with promoter, FII, and DII holdings.
Check Eris Lifesciences promoter holding and ownership changes for ERIS on TickJournal.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 53.92% | 54.85% | 54.83% | 54.85% | 54.85% | 54.90% | 54.88% | 54.87% |
| FII Holding | 6.39% | 8.43% | 8.40% | 7.21% | 6.85% | 14.27% | 14.59% | 8.01% |
| DII Holding | 20.35% | 18.07% | 18.17% | 19.36% | 20.32% | 15.63% | 16.23% | 18.64% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 10.06% | 9.16% | 9.12% | 9.12% | 8.51% | 14.24% | 13.53% | 10.51% |
| Other Holding | 9.26% | 9.49% | 9.47% | 9.45% | 9.48% | 0.95% | 0.77% | 7.96% |
| Shareholder Count | 51,656 | 50,087 | 52,225 | 59,438 | 54,713 | 51,753 | 44,176 | 46,346 |
Eris Lifesciences Share Dividend Screener - Share Yield Analysis
Check Eris Lifesciences dividend history with payout and yield data.
View Eris Lifesciences dividend details including ex-dates and amounts for ERIS stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹7.35 | 0.57% |
| 2024-March | ₹0.00 | 0.00% |
| 2023-March | ₹7.35 | 0.87% |
| 2022-March | ₹6.01 | 1.05% |
| 2021-March | ₹5.50 | 0.80% |
| 2020-March | ₹2.87 | 0.47% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Eris Lifesciences Stock Index Membership
See which indices include Eris Lifesciences stock.
Check ERIS index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE INDEX BSE HC
BSE INDEX BSE500
BSE INDEX MSL400
BSE INDEX SML250
BSE INDEX SMLCAP
NIFTY 500
NIFTY MIDSML 400
NIFTY SMALLCAP250 MOMENTUM QUALITY 100
NIFTY SMLCAP 250
NIFTY TOTAL MKT
NIFTY500 EQUAL WEIGHT
NIFTY500 LARGEMIDSMALL EQUAL CAP WEIGHTED
NIFTY500 MULTICAP
Eris Lifesciences Market Events Screener - Corporate Actions
Get Eris Lifesciences corporate actions including splits, bonuses, and buybacks.
Check Eris Lifesciences stock events that may affect ERIS share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | -9.82% | ||
| 2026-05-29 | 2026-05-29 | Dividend | ₹ 7.21 /share | 1.29% |
| 2026-05-20 | 2026-05-20 | Quarterly Result Announcement | NA | -2.81% |
| 2026-02-13 | 2026-02-13 | Quarterly Result Announcement | NA | 6.90% |
| 2025-11-12 | 2025-11-12 | Quarterly Result Announcement | NA | -0.28% |
| 2025-08-05 | 2025-08-05 | Quarterly Result Announcement | NA | 0.55% |
| 2025-07-25 | 2025-07-25 | Annual General Meeting | NA | 6.29% |
| 2025-05-19 | 2025-05-19 | Quarterly Result Announcement | NA | 4.50% |
| 2025-02-13 | 2025-02-13 | Dividend | ₹ 7.35 /share | -10.84% |
| 2025-02-04 | 2025-02-04 | Quarterly Result Announcement | NA | 7.93% |
| 2024-10-25 | 2024-10-25 | Quarterly Result Announcement | NA | -3.41% |
| 2022-08-11 | 2022-08-16 | Dividend | ₹ 7.35 /share | -0.23% |
| 2021-08-05 | 2021-08-06 | Dividend | ₹ 6.01 /share | 0.77% |
Eris Lifesciences Competitors Screener - Peer Comparison
Screen ERIS competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 441,574 | 40.42 | 58,220 | 6.38% | 11,565 | 54.03 |
| Divis Laboratories | 179,178 | 73.73 | 10,560 | 8.73% | 2,520 | 57.30 |
| Torrent Pharmaceuticals | 150,754 | 66.80 | 13,753 | 19.18% | 2,028 | 66.36 |
| Cipla | 114,592 | 29.26 | 27,712 | -2.46% | 3,783 | 64.19 |
| Dr Reddys Laboratories | 111,091 | 26.24 | 33,593 | -0.44% | 3,998 | 57.44 |
| Zydus Life Science | 108,789 | 20.40 | 26,720 | 13.65% | 5,242 | 73.90 |
| Lupin | 103,648 | 19.46 | 27,488 | 19.98% | 5,345 | 48.15 |
| Mankind Pharma | 100,155 | 52.84 | 14,278 | 12.03% | 1,750 | 59.66 |
| Aurobindo Pharma | 84,466 | 24.29 | 33,385 | 3.21% | 3,376 | 51.11 |
| Laurus Labs | 74,182 | 81.46 | 6,813 | 21.03% | 884 | 78.36 |
Eris Lifesciences Company Announcements - News Screener
Screen ERIS latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot | - | |
| Shareholder Meeting / Postal Ballot-Scrutinizer"s Report | - | |
| 2026-05-28 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-05-24 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-05-23 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-05-23 | Announcement under Regulation 30 (LODR)-Date of payment of Dividend | - |
| 2026-05-23 | Corporate Action-Board approves Dividend | - |
| 2026-05-23 | Financial Results For The Quarter And Financial Year Ended March 31 2026 | - |
| 2026-05-23 | Board Meeting Outcome for Outcome Of Board Meeting | - |
| 2026-05-19 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-05-15 | Board Meeting Intimation for Consideration Of Financial Results And Interim Dividend | - |
| 2026-05-12 | Credit Rating Of Eris Threpeutics Limited | - |
| 2026-05-11 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | - |
| 2026-05-08 | Announcement under Regulation 30 (LODR)-Credit Rating | - |
| 2026-04-24 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-04-23 | Shareholder Meeting / Postal Ballot-Notice of Postal Ballot | - |
| 2026-04-20 | INSPECTION OF SWISS PARENTERALS UNITS 1 AND 2 BY HALMED CROATIA | - |
| 2026-04-10 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-03-31 | Closure Of The Transaction Related To Acquisition Of Probiotics Business Of Velbiom Probiotics Private Limited. | - |
| 2026-03-27 | Closure of Trading Window | - |